Singer Sylvia T, Vichinsky Elliott P, Larkin Sandra, Olivieri Nancy, Sweeters Nancy, Kuypers Frans A
Hematology/Oncology Department and Clinical Research Center at Oakland, CA, USA.
Am J Hematol. 2008 Nov;83(11):842-5. doi: 10.1002/ajh.21266.
In thalassemia, fetal hemoglobin (HbF) augmentation with hydroxycarbamide (also known as hydroxyurea) is not always successful. The expected parallel effects on red cell (RBC) membrane deformability, cell hydration, and membrane phospholipid organization, all important for extending RBC life span and increasing Hb, have been infrequently examined. We analyzed these characteristics in 15 nontransfused E/beta(0) thalassemia patients treated with HU (mean 10.2 months). Membrane deformability and cell hydration mildly improved in association with increased HbF levels approaching statistical significance (r = 0.51, P = 0.06). All measures improved considerably in splenctomized patients. These findings underscore the disappointing results of hydroxyurea treatment in clinical trials and the importance of examining the effect on RBC characteristics for the development and understanding of HbF-enhancing agents.
在地中海贫血中,使用羟基脲(也称为羟基尿素)增加胎儿血红蛋白(HbF)并非总是成功的。对红细胞(RBC)膜变形性、细胞水合作用和膜磷脂组织的预期平行效应,这些对延长RBC寿命和增加Hb都很重要,但很少被研究。我们分析了15例接受HU治疗(平均10.2个月)的非输血E/β(0)地中海贫血患者的这些特征。随着HbF水平升高,膜变形性和细胞水合作用略有改善,接近统计学意义(r = 0.51,P = 0.06)。脾切除患者的所有指标均有显著改善。这些发现强调了羟基脲治疗在临床试验中令人失望的结果,以及研究对RBC特征的影响对于开发和理解HbF增强剂的重要性。